Abstract

In recent decades, research on the therapeutic potential of progenitor cells has advanced considerably. Among progenitor cells, mesenchymal stromal cells (MSCs) have attracted significant interest and have proven to be a promising tool for regenerative medicine. MSCs are isolated from various anatomical sites, including bone marrow, adipose tissue, and umbilical cord. Advances in separation, culture, and expansion techniques for MSCs have enabled their large-scale therapeutic application. This progress accompanied by the rapid improvement of transplantation practices has enhanced the utilization of MSCs in regenerative medicine. During tissue healing, MSCs may exhibit several therapeutic functions to support the repair and regeneration of injured tissue. The process underlying these effects likely involves the migration and homing of MSCs, as well as their immunotropic functions. The direct differentiation of MSCs as a cell replacement therapeutic mechanism is discussed. The fate and behavior of MSCs are further regulated by their microenvironment, which may consequently influence their repair potential. A paracrine pathway based on the release of different messengers, including regulatory factors, chemokines, cytokines, growth factors, and nucleic acids that can be secreted or packaged into extracellular vesicles, is also implicated in the therapeutic properties of MSCs. In this review, we will discuss relevant outcomes regarding the properties and roles of MSCs during tissue repair and regeneration. We will critically examine the influence of the local microenvironment, especially immunological and inflammatory signals, as well as the mechanisms underlying these therapeutic effects. Importantly, we will describe the interactions of local progenitor and immune cells with MSCs and their modulation during tissue injury. We will also highlight the crucial role of paracrine pathways, including the role of extracellular vesicles, in this healing process. Moreover, we will discuss the therapeutic potential of MSCs and MSC-derived extracellular vesicles in the treatment of COVID-19 (coronavirus disease 2019) patients. Overall, this review will provide a better understanding of MSC-based therapies as a novel immunoregenerative strategy.

Highlights

  • Mesenchymal stromal cells (MSCs) are currently one of the most extensively investigated therapeutic cellular products for clinical applications

  • Exosome-laden scaffolds proactively facilitated tissue repair in mice skin injury models by favoring M2/TH2/Treg responses (Su et al, 2021). All these findings indicate that combined hyaluronic acid (HA) and MSCs may constitute an effective strategy in regenerative medicine

  • In the context of bone engrafting and cell-based therapeutic applications, MSCs have been differentiated into phenotypes that are similar to pericytes, which promote angiogenesis through direct cell–cell contact (Julier et al, 2017)

Read more

Summary

Introduction

Mesenchymal stromal cells (MSCs) are currently one of the most extensively investigated therapeutic cellular products for clinical applications. MSCs can detect the microenvironment of the injured area and release various paracrine soluble factors that conduct numerous functions (such as anti-inflammatory, antiapoptotic, antifibrotic, antibacterial, and antioxidant effects) to promote the regeneration and repair of the injured tissue.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call